» Articles » PMID: 20954799

Oxidative Pathways As a Drug Target for the Treatment of Autism

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2010 Oct 20
PMID 20954799
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Importance Of The Field: Autism is a severe, pervasive developmental disorder, the aetiology of which is poorly understood. Current pharmacological treatment options for autism are often focused on addressing comorbid behavioural problems, rather than core features of the disorder. Investigation of a new treatment approach is needed.

Areas Covered In This Review: Recent research has indicated a possible role of abnormalities in oxidative homeostasis in the pathophysiology of autism, based on reports that a range of oxidative biomarkers are significantly altered in people with autism. This article reviews the current findings on oxidative stress in autism, including genetic links to oxidative pathways, changes in antioxidant levels and other oxidative stress markers. We conducted a search of the literature up to June 2010, using Medline, Pubmed, PsycINFO, CINAHL PLUS and BIOSIS Previews.

What The Reader Will Gain: This review provides an overview of the current understanding of the role of oxidative stress in autism. This will assist in highlighting areas of future therapeutic targets and potential underlying pathophysiology of this disorder.

Take Home Message: Abnormalities in oxidative homeostasis may play a role in the pathophysiology of autism. Antioxidant treatment may form a potential therapeutic pathway for this complex disorder.

Citing Articles

Sleep Problems and 6-Sulfatoxymelatonin as Possible Predictors of Symptom Severity, Adaptive and Maladaptive Behavior in Children with Autism Spectrum Disorder.

Bartakovicova K, Kemenyova P, Belica I, Janik Szapuova Z, Stebelova K, Waczulikova I Int J Environ Res Public Health. 2022; 19(13).

PMID: 35805248 PMC: 9265882. DOI: 10.3390/ijerph19137594.


Improvement of the Clinical and Psychological Profile of Patients with Autism after Methylcobalamin Syrup Administration.

corejova A, Fazekas T, Janosikova D, Repisky J, Pospisilova V, Mikova M Nutrients. 2022; 14(10).

PMID: 35631176 PMC: 9144375. DOI: 10.3390/nu14102035.


Adolescent GBR12909 exposure induces oxidative stress, disrupts parvalbumin-positive interneurons, and leads to hyperactivity and impulsivity in adult mice.

Khan A, de Jong L, Kamenski M, Higa K, Lucero J, Young J Neuroscience. 2016; 345:166-175.

PMID: 27890827 PMC: 5316310. DOI: 10.1016/j.neuroscience.2016.11.022.


Autism biomarkers: challenges, pitfalls and possibilities.

Anderson G J Autism Dev Disord. 2014; 45(4):1103-13.

PMID: 25193140 DOI: 10.1007/s10803-014-2225-4.


Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.

Lee Y, Oh S, Park C, Hong M, Lee A, Yoo H Clin Psychopharmacol Neurosci. 2014; 12(1):19-30.

PMID: 24851117 PMC: 4022762. DOI: 10.9758/cpn.2014.12.1.19.